Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Genentech, Sanofi Ink Academic Pacts

by Rick Mullin
March 1, 2010 | A version of this story appeared in Volume 88, Issue 9

The University of California, San Francisco, has formed a partnership with Genentech to discover drugs for neurodegenerative diseases. Genentech will provide funding and know-how in support of researchers at UCSF’s Small Molecule Discovery Center. In addition to undisclosed initial funding, UCSF could receive up to $13 million in milestone payments from Genentech. Separately, Sanofi-Aventis has formed a research agreement with the French Life Sciences & Healthcare Alliance and a sponsorship program with France’s National Institute of Health & Medical Research to support young researchers setting up labs in France. Sanofi says it will invest as much as $65 million in the two programs over five years.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.